Article
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Nature communications - 19 Aug 2021
Risbridger Gail P, Clark Ashlee K, Porter Laura H, Toivanen Roxanne, Bakshi Andrew, Lister Natalie L, Pook David, Pezaro Carmel J, Sandhu Shahneen, Keerthikumar Shivakumar, Quezada Urban Rosalia, Papargiris Melissa, Kraska Jenna, Madsen Heather B, Wang Hong, Richards Michelle G, Niranjan Birunthi, O'Dea Samantha, Teng Linda, Wheelahan William, Li Zhuoer, Choo Nicholas, Ouyang John F, Thorne Heather, Devereux Lisa, Hicks Rodney J, Sengupta Shomik, Harewood Laurence, Iddawala Mahesh, Azad Arun A, Goad Jeremy, Grummet Jeremy, Kourambas John, Kwan Edmond M, Moon Daniel, Murphy Declan G, Pedersen John, Clouston David, Norden Sam, Ryan Andrew, Furic Luc, Goode David L, Frydenberg Mark, Lawrence Mitchell G, Taylor Renea A
Abstract excerpt
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.